Intellia Therapeutics, Inc. (NTLA) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
40 ERIE STREET CAMBRIDGE, MA 02139 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 601,515 | 912,223 | 1,192,622 | 748,688 | 597,371 | 279,726 | |||
| Cash and cash equivalent | 189,182 | 226,748 | 523,506 | 123,406 | 160,020 | 57,226 | |||
| Short-term investments | 412,333 | 685,475 | 669,116 | 625,282 | 437,351 | 222,500 | |||
| Receivables | 8,517 | 36,456 | 4,068 | 2,131 | 2,130 | 4,620 | |||
| Prepaid expense | 4,410 | 1,190 | 1,367 | 1,393 | |||||
| Other undisclosed current assets | 25,421 | 48,461 | 18,740 | 17,091 | 17,016 | 5,135 | |||
| Total current assets: | 639,863 | 998,330 | 1,216,797 | 769,303 | 616,517 | 289,481 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 219,292 | 115,375 | 133,076 | 79,143 | 39,114 | 19,137 | |||
| Property, plant and equipment | 27,381 | 32,760 | 27,921 | 20,968 | 15,943 | 17,996 | |||
| Long-term investments and receivables | 260,215 | 111,629 | 101,793 | 395,492 | 4,746 | ||||
| Long-term investments | 260,215 | 111,629 | 101,793 | 395,492 | 4,746 | ||||
| Other noncurrent assets | 4,748 | 2,920 | |||||||
| Other undisclosed noncurrent assets | 44,264 | 42,883 | 40,527 | 29,558 | |||||
| Total noncurrent assets: | 551,152 | 302,647 | 303,317 | 525,161 | 59,805 | 44,799 | |||
| TOTAL ASSETS: | 1,191,015 | 1,300,977 | 1,520,114 | 1,294,464 | 676,322 | 334,280 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 69,944 | 74,469 | 66,030 | 52,962 | 36,014 | 17,214 | |||
| Accounts payable | 14,589 | 7,452 | 5,154 | 9,653 | 10,460 | 3,941 | |||
| Accrued liabilities | 55,355 | 67,017 | 60,876 | 43,309 | 25,554 | 13,273 | |||
| Deferred revenue | 20,661 | 22,140 | 43,839 | 63,759 | 22,544 | 12,674 | |||
| Debt | 5,745 | ||||||||
| Due to related parties | ✕ | ✕ | ✕ | 1,600 | |||||
| Other undisclosed current liabilities | 20,246 | 18,599 | 15,085 | 9,112 | 5,696 | ||||
| Total current liabilities: | 110,851 | 115,208 | 126,554 | 125,833 | 64,254 | 35,633 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 64,911 | 33,609 | 12,630 | ||||||
| Liabilities, other than long-term debt | 208,208 | 135,600 | 157,976 | 63,476 | 51,387 | 16,136 | |||
| Deferred revenue | 18,256 | 38,853 | 19,932 | 63,476 | 51,387 | 16,136 | |||
| Operating lease, liability | 189,952 | 96,747 | 114,018 | 64,911 | 33,609 | 12,630 | |||
| Business combination, contingent consideration, liability | 24,026 | ||||||||
| Total noncurrent liabilities: | 208,208 | 135,600 | 157,976 | 128,387 | 84,996 | 28,766 | |||
| Total liabilities: | 319,059 | 250,808 | 284,530 | 254,220 | 149,250 | 64,399 | |||
| Equity | |||||||||
| Equity, attributable to parent | 871,956 | 1,050,169 | 1,235,584 | 1,040,244 | 527,072 | 269,881 | |||
| Common stock | 10 | 9 | 9 | 7 | 7 | 5 | |||
| Additional paid in capital | 3,048,741 | 2,710,797 | 2,420,223 | 1,745,870 | 962,173 | 570,493 | |||
| Accumulated other comprehensive income (loss) | 605 | (2,258) | (7,461) | (2,632) | 1 | 261 | |||
| Accumulated deficit | (2,177,400) | (1,658,379) | (1,177,187) | (703,001) | (435,109) | (300,878) | |||
| Total equity: | 871,956 | 1,050,169 | 1,235,584 | 1,040,244 | 527,072 | 269,881 | |||
| TOTAL LIABILITIES AND EQUITY: | 1,191,015 | 1,300,977 | 1,520,114 | 1,294,464 | 676,322 | 334,280 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 57,877 | 36,275 | 52,121 | 33,053 | 57,994 | 43,103 | ||
| Revenue from related parties | ✕ | ✕ | ✕ | 21,134 | 6,072 | |||
| Cost of revenue | (76) | (162) | ||||||
| Gross profit: | 57,801 | 36,275 | 51,959 | 33,053 | 57,994 | 43,103 | ||
| Operating expenses | (592,064) | (551,566) | (510,123) | (300,903) | (194,577) | (149,471) | ||
| Operating loss: | (534,263) | (515,291) | (458,164) | (267,850) | (136,583) | (106,368) | ||
| Nonoperating income (expense) | 15,242 | 34,099 | (16,022) | 1,325 | 2,352 | 6,835 | ||
| Investment income, nonoperating | 1,283 | 2,352 | 6,835 | |||||
| Other nonoperating income (expense) | 15,242 | 34,099 | (16,022) | 42 | ||||
| Loss from continuing operations before equity method investments, income taxes: | (519,021) | (481,192) | (474,186) | (266,525) | (134,231) | (99,533) | ||
| Income from equity method investments | 1,325 | |||||||
| Loss from continuing operations: | (519,021) | (481,192) | (474,186) | (265,200) | (134,231) | (99,533) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (265,200) | (134,231) | (99,533) | |
| Other undisclosed net loss | (2,692) | |||||||
| Net loss available to common stockholders, diluted: | (519,021) | (481,192) | (474,186) | (267,892) | (134,231) | (99,533) | ||
Comprehensive Income ($ in thousands)
| 9/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (519,021) | (481,192) | (474,186) | (267,892) | (134,231) | (99,533) | ||
| Comprehensive loss: | (519,021) | (481,192) | (474,186) | (267,892) | (134,231) | (99,533) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 731 | 5,203 | (4,829) | (2,633) | (260) | 289 | ||
| Comprehensive loss, net of tax, attributable to parent: | (518,290) | (475,989) | (479,015) | (270,525) | (134,491) | (99,244) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.